---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: V-0046"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: V-0046. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 30 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence/v-0046"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: V-0046

<a id="heading-3.1.6"></a>

## 3.1.6 V-0046

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Registered study purpose

> “The main purpose of this research study is to evaluate the safety and dosing of CG0070.”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.1-2"></a>

#### Purpose stated in the phase 1 publication

> “We assessed the safety, pharmacokinetics and anticancer activity of intravesical CG0070, a cancer selective, replication competent adenovirus, for the treatment of nonmuscle invasive bladder cancer.”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Registered study dates, sponsor, and sites

| Field | Quoted record |
| --- | --- |
| Study start | “2005-04” |
| Primary completion (estimated) | “2008-10” |
| Study completion (estimated) | “2010-09” |
| Number of sites | “This study has 10 locations” |

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Registered design: phase 1 dose escalation

> “A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure”
> “Cohorts of three to six patients will be assigned to receive intravesical (into the bladder) administration of CG0070 either Weekly or Every 4 Weeks for up to a total of 6 doses.”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.3-2"></a>

#### Registered design details

| Field | Quoted record |
| --- | --- |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.3-3"></a>

#### Single-dose and multi-dose schedules

> “This trial evaluated the safety and feasibility of single and multiple doses of CG0070. Multi-dose regimens were tested at two schedules: every 4 weeks or weekly.”

Source: [Burke et al. (2010)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)37476-7)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Inclusion criteria

> “High grade non-muscle invasive bladder cancer (stages Ta, T1 and/or CIS - carcinoma in situ). High grade being defined as G2 or G3 disease.”
> “Failure of at least one prior treatment with BCG, defined as evidence of TCC on cystoscopic exam and biopsy or cystoscopic exam and urine cytology at least 6 weeks from last BCG treatment”
> “ECOG performance status 0-1”
> “Adequate bone marrow, renal, liver and coagulation function”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.4-2"></a>

#### Exclusion criteria

> “Use of anticoagulants such as coumadin or heparin”
> “Active systemic autoimmune disease or chronic immunodeficiency”
> “Prior gene therapy”
> “Uncontrolled cystitis, bladder pain, bladder spasms, urinary incontinence, or reduced bladder volume”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### Dose levels and schedules administered

> “A total of 35 patients received single or multiple (every 28 days × 3 or weekly × 6) intravesical infusions of CG0070 at 1 of 4 dose levels (1 × 10(12), 3 × 10(12), 1 × 10(13) or 3 × 10(13) viral particles).”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="topic-3.1.6.5-2"></a>

#### Pretreatment with dodecyl-maltoside

> “All patients receive dodecyl-maltoside, a mild detergent, prior to CG0070 to enhance penetration of the mucosal layer.”

Source: [Senzer et al. (2006)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(06)00324-8)

<a id="topic-3.1.6.5-3"></a>

#### Registered intervention

> “Intravesical administration of CG0070 (in suspension) directly into the bladder”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Maximum Tolerated Dose as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

##### Registered primary endpoint: maximum tolerated or maximum feasible dose

> “Maximum-tolerated or maximum feasible dose in single and multidose regimens of CG0070 by intravesical administration”
> “Assessment of the amount of CG0070 in the urine and blood over time by PCR”

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.6.1-2"></a>

##### Primary goals stated at study start: safety and maximum tolerated dose

> “The primary goals for this study of intravesical (IVE) CG0070 in patients with existing TCC after BCG failure is the evaluation of safety and the identification of a maximum tolerated dose.”
> “Assessment of response rate and progression free survival is also planned.”

Source: [Senzer et al. (2006)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(06)00324-8)

<a id="topic-3.1.6.6.1-3"></a>

##### Response and pharmacokinetic assessments

> “Response to treatment was based on cystoscopic assessment and biopsy or urine cytology.”
> “Urine and plasma CG0070, and granulocyte-monocyte colony-stimulating factor were measured in all patients.”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Registered enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (estimated) | “75” |

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655)

<a id="topic-3.1.6.7.1-2"></a>

##### Participants treated

> “A total of 35 patients received single or multiple (every 28 days × 3 or weekly × 6) intravesical infusions of CG0070”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

##### Retinoblastoma phosphorylation subset

> “A subset of 18 patients was assessed for retinoblastoma phosphorylation status.”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

##### Participants treated by schedule and dose range

> “35 patients (pts) were treated with CG0070 at doses ranging from 1012 to 3 x 1013 viral particles (vp) in the single dose schedule, and from 1012 to 1013 vp per dose in the weekly x 6 and every 4 week x 3 cohorts.”

Source: [Burke et al. (2010)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)37476-7)

<a id="topic-3.1.6.8.1-2"></a>

##### Interim accrual by schedule

> “Thirteen patients have been treated with intravesical single dose CG0070 up to 3×1013 viral particles [vp]; 9 pts have been treated with a multi-dose schedule at the first dose level (1×1012 vp) at one of two schedules: 6 administrations given weekly or 3 administrations given once every 4 weeks.”

Source: [Nemunaitis et al. (2008)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)40090-0)

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

##### Tumor stage of enrolled participants

> “N = 35 NMIBC CIS-containing or Ta/T1”

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

Additional sources: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

##### Complete response rate and duration: phase 1 publication

> “The complete response rate and median duration of the complete response across cohorts was 48.6% and 10.4 months, respectively.”
> “In the multidose cohorts the complete response rate for the combined groups (every 28 days and weekly × 6) was 63.6% (14 of 22 patients).”
> “In an exploratory, retrospective assessment patients with borderline or high retinoblastoma phosphorylation who received the multidose schedules had an 81.8% complete response rate (9 of 11).”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="topic-3.1.6.8.3-2"></a>

##### Complete response rate: congress report

> “A complete response rate (RR) of 46% was observed for all pts.”

Source: [Burke et al. (2010)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)37476-7)

<a id="topic-3.1.6.8.3-3"></a>

##### Complete response at 3 months by schedule: company presentation

| Schedule | Complete response at 3 months |
| --- | --- |
| Single dose | “3/13 (23%)” |
| Every 28 days | “6/13 (46%)” |
| Weekly × 6 | “7/9 (78%)” |
| Multi-dose (every 28 days and weekly × 6) | “13/22 (59%)” |
| Total | “16/35 (46%)” |

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-3.1.6.8.3-4"></a>

##### Complete response at 3 months by dose: company presentation

| Dose | Complete response at 3 months |
| --- | --- |
| 1 × 10^12 viral particles | “8/13 (62%)” |
| 3 × 10^12 viral particles | “4/9 (44%)” |
| 1 × 10^13 viral particles | “4/10 (40%)” |
| 3 × 10^13 viral particles | “0/3 (0%)” |

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-3.1.6.8.3-5"></a>

##### Duration of complete response: company presentation

> “Median Duration: 8.4 months, with responses ongoing at 17.0 months”

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-3.1.6.8.3-6"></a>

##### Urine GM-CSF and viral genome measurements

> “High levels of granulocyte-monocyte colony-stimulating factor were detected in urine after administration in all patients.”
> “Virus replication was suggested based on an increase in urine CG0070 genomes between days 2 and 5 in 58.3% of tested patients (7 of 12).”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

##### Adverse events and maximum tolerated dose: phase 1 publication

> “Grade 1-2 bladder toxicities were the most common adverse events observed.”
> “A maximum tolerated dose was not reached.”

Source: [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/)

<a id="topic-3.1.6.8.5-2"></a>

##### Dose-limiting toxicity and flu-like illness: congress report

> “No SAEs and only one dose limiting toxicity was reported, gr 3 lymphopenia, at a dose of 1012 vp on the every 4 week schedule.”
> “Transient, local bladder related toxicities were the most common adverse events reported including dysuria, hematuria, urgency, bladder spasm, nocturia, and pain.”
> “Flu-like illness was also observed in 10–20% of patients including fever, chills, fatigue, and myalgias.”
> “The maximum tolerated dose was not reached in the single or multi-dose cohorts.”

Source: [Burke et al. (2010)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)37476-7)

<a id="topic-3.1.6.8.5-3"></a>

##### Adverse events at the first multi-dose level: interim congress report

> “In the multi-dose schedules at dose level 1, common related, adverse events include bladder discomfort, hematuria, dysuria, fatigue, tissue excretion, urgency, and frequency (all grade 1/2).”
> “There has been 1 episode of grade 3 transient lymphopenia in a patient receiving multidose CG0070 after the 3rd dose and no grade 4 toxicities noted.”

Source: [Nemunaitis et al. (2008)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)40090-0)

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary: limitations of V-0046

- Design: V-0046 was a phase 1, open-label, non-randomized dose-escalation study in 35 participants, with cohorts of three to six participants at each dose and schedule, so efficacy estimates rest on small subgroups (for example, 9 participants on the weekly × 6 schedule).
- Population: eligibility required failure of at least one prior BCG treatment and allowed G2 disease, which differs from the BCG-unresponsive definition used in BOND-003.
- Reported results differ by source: the 2012 publication reports a complete response rate of 48.6% with a median duration of 10.4 months, a 2010 congress report gives 46%, and a 2023 company presentation gives 16 of 35 participants (46%) at 3 months with a median duration of 8.4 months. The multi-dose complete response rate is 63.6% (14 of 22) in the publication and 13 of 22 (59%) in the presentation.
- The association between retinoblastoma phosphorylation and response (81.8%, 9 of 11) comes from an exploratory, retrospective assessment of a subset of 18 participants.
- The registry record lists an estimated primary completion in October 2008 and an estimated enrollment of 75 participants, against 35 participants treated.
- Only the abstract of the 2012 publication is openly available.

Source: [ClinicalTrials.gov NCT00109655](https://clinicaltrials.gov/study/NCT00109655); [Burke et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23088985/); [Burke et al. (2010)](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)37476-7); [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
